Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 9/20 | 0.45 |
| ▸ | CTSS | P25774 | 7/20 | 0.45 |
| ▸ | CTSK | P43235 | 3/20 | 0.45 |
| ▸ | CTSB | P07858 | 2/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CTSV | O60911 | 2/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | REN | P00797 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5484032 | 0.93 | RAB9A (0.41) | CTSLCTSSCTSKCTSBUSP30 | |
| SCHEMBL4188282 | 0.89 | CTSS (0.54) | CTSLCTSSCTSKCTSBUSP30 | |
| SCHEMBL5487435 | 0.87 | CTSL (0.40) | CTSLCTSSCTSKCTSBRAB9A | |
| SCHEMBL4178441 | 0.84 | CTSL (0.47) | CTSLCTSSCTSKCTSBRAB9A | |
| SCHEMBL4188373 | 0.83 | CTSS (0.39) | CTSLCTSSCTSKCTSBRAB9A | |
| SCHEMBL4175687 | 0.82 | CNR1 (0.44) | CTSLCTSSCTSKRAB9AALDH1A1 | |
| SCHEMBL4171001 | 0.81 | ATM (0.41) | RAB9AALDH1A1LMNAATMREN | |
| SCHEMBL4181130 | 0.80 | CTSS (0.48) | CTSLCTSSCTSKCTSBALDH1A1 | |
| SCHEMBL4191791 | 0.80 | CTSB (0.42) | CTSLCTSSCTSKCTSBATM | |
| SCHEMBL4171002 | 0.80 | CTSL (0.49) | CTSLCTSSCTSKCTSBUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124619-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-05-14 | — | — | US | claimed |
| US-20090124619-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124619-A1 | NOVEL COMPOUNDS | TRPV4, TRPC4, TRPV1 | CTSL 867/4885CTSS 1717/4885CTSK 1738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.